Informational Only · Not Legal Advice · No Attorney-Client Relationship · Editorial Policy

A Spinal Cord Stimulator Causing Unexpected Nerve Injury: Settlement, Trial, and Appeal Issues Explained

A spinal cord stimulator is an implanted device that sends electrical current to block pain signals, but it can also cause unexpected nerve injury. That injury has not led to a global manufacturer payout, while trials face strict proof and federal preemption limits and appeals enforce expert and consumer-protection rules. DrugWatch reports these devices can cause nerve damage, painful shocks or burns, lead migration or fracture, loss of therapy, infection, and revision or removal surgery in its DrugWatch device guide. This article explains how the injury happens, what cases are worth now, where group cases stand, and what trial and appeal courts require.

Table of Contents

How a pain blocker can damage nerves

Leads sit near the spinal cord and deliver steady pulses. Movement, mechanical stress, or anchor-site strain can shift, fracture, or misdirect a lead.

The result can be new pain, weakness, shock sensations, or loss of prior relief. Warning signs after implant often include: Revision surgery does not prove a defect. It does create records of device position, integrity, pain change, and function that later shape causation and damages.

  • new burning, shooting pain, numbness, or weakness
  • sudden shocks, overstimulation, or loss of stimulation
  • wound redness, fever, swelling, or drainage
  • reduced function that requires reprogramming, revision, or removal

What settlements actually show

DrugWatch reported in its November 2026 update that no major manufacturer verdict or global settlement had occurred for failure-to-warn or defect claims, while a 2024 malpractice case settled for $1.25 million after bowel dysfunction and partial paralysis in its DrugWatch lawsuit update. That contrast matters for expectations.

Individual value turns on diagnosis, permanence, added care, lost work, and whether the device must stay, be revised, or be removed. A temporary stimulation problem is not priced like permanent nerve injury with paralysis, bowel harm, or lifetime care. Keep implant records, programming logs, imaging, operative notes, and work limits together from the start.

Where group litigation stands

Federal cases against Boston Scientific are centralized as MDL 3181 in the Central District of California, created June 5, 2026, with later MDLs against Abbott and Nevro created October 2, 2026, while Medtronic cases remain outside, according to TorHoerman Law in its TorHoerman Law MDL summary. Centralization coordinates discovery and early rulings without merging each person's injury claim.

A separate lead issue affects pain patients with implanted systems. MedTech Dive reported a September 2026 Class I recall of Boston Scientific Infinion CX leads after 1,081 serious injuries tied to mechanical stress and fracture at the anchor site. AboutLawsuits reported the recall covers unused leads and does not require removal of already-implanted leads.

Why injury trials face a federal barrier

Most stimulators are Class III devices approved through federal premarket approval. Under Riegel v. Medtronic, 552 U.S. 312, state claims that would impose different or additional requirements may be expressly preempted, TorHoerman Law's JPML analysis explains.

That defense can narrow warnings, design, and manufacturing theories before a jury hears them. Surviving claims usually focus on what federal law already requires, such as parallel violations, plus proof tied to the specific device and implant. General injury statistics, an Associated Press finding of more than 80,000 reports from 2008 to 2018, and recall news alone do not establish what caused one person's nerve damage. Ask early whether counsel plans a parallel-claim path and which device-specific evidence supports it.

What appeals require to survive dismissal

On March 25, 2026, the Ninth Circuit affirmed dismissal in Hunt v. Medtronic USA, No. 25-1350, holding the negligence claim lacked expert causation and the Washington Consumer Protection Act claim lacked public impact, as shown in the Ninth Circuit opinion via Justia. The court did not decide that stimulators cannot injure nerves.

The practical lesson is direct. Obtain a qualified medical or engineering opinion that links the specific device behavior to the specific nerve injury. For a consumer-protection claim, preserve facts showing broader public effect, not only a private treatment dispute. Bring both issues with supporting declarations before the trial court rules.


You Might Also Like

We use essential cookies to make this site work and remember your preferences. We do not use advertising or analytics cookies. Privacy Policy.